Survival after Lung Metastasectomy from Urothelial Carcinoma: A Multi-Institutional Database Study
Authors:
- Yoshikane YamauchiYoshikane Yamauchi
- Masaaki SatoMSMasaaki Sato
- Takekazu IwataTITakekazu Iwata
- Makoto EndoMEMakoto Endo
- Norihiko IkedaNINorihiko Ikeda
- Hiroshi HashimotoHHHiroshi Hashimoto
- Tai HatoTHTai Hato
- Hidemi SuzukiHSHidemi Suzuki
- Haruhisa MatsugumaHMHaruhisa Matsuguma
- Yasushi ShintaniYasushi Shintani
- Haruhiko KondoHKHaruhiko Kondo
- Takahiko OyamaTOTakahiko Oyama
Open Access
Abstract
Background/objectives: The efficacy of lung metastasectomy in patients with urothelial carcinoma remains inconclusive, as there is only limited evidence from small studies. In this study, we aimed to assess the prognostic outcomes of excising pulmonary metastases from urothelial carcinoma. Methods: In this study, we utilized data from the Metastatic Lung Tumor Study Group of Japan database, a multi-institutional prospective database of pulmonary metastasectomies. We examined the data of patients who had undergone pulmonary metastasectomy for urothelial carcinoma between 1985 and 2021. Exclusion criteria included insufficient clinical information and follow-up of <3 months. Results: The study cohort comprised 100 patients (63 bladder cancer, 37 renal pelvic and ureteral cancer), with a median follow-up of 34 months. There were 70 male and 30 female patients of average age 66.5 ± 10.4 years at lung metastasectomy. The median interval from treatment of the primary lesion to metastasectomy was 19 months and the maximum tumor diameter was 21 ± 15 mm. Three- and five-year overall survival rates were 69% and 59%, respectively. Three- and five-year disease-free survival rates were 56% and 46%, respectively. Multivariate analysis identified larger tumor diameter (hazard ratio: 1.62, 95% confidence interval: 1.21–2.17) and distant metastases at the time of treatment of the primary cancer (hazard ratio: 4.23; 95% confidence interval: 1.54–11.6) as significant adverse prognostic factors for overall survival. Conclusions: To our knowledge, this is the largest published case series of pulmonary resection for metastatic urothelial carcinoma, providing benchmark data for the assessment of long-term outcomes of this rare entity.Keywords
This publication has 37 references indexed in Scilit:
- Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort AnalysisClinical Genitourinary Cancer, 2022
- Prognostic Analysis of Surgical Resection for Pulmonary Metastasis from Hepatocellular CarcinomaWorld Journal of Surgery, 2016
- Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract CancerClinical Genitourinary Cancer, 2015
- Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years oldVirchows Archiv, 2015
- Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the CommunityClinical Genitourinary Cancer, 2012
- Is There a Role for Pulmonary Metastasectomy With a Curative Intent in Patients With Metastatic Urinary Transitional Cell Carcinoma?The Annals of Thoracic Surgery, 2011
- Current status of pulmonary metastasectomyEuropean Journal of Cardio-Thoracic Surgery, 2011
- Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell CarcinomasThe Annals of Thoracic Surgery, 2009
- Surgical outcomes for pulmonary metastases from hepatocellular carcinomaEuropean Journal of Cardio-Thoracic Surgery, 2008
- Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomesInternational Journal of Clinical Oncology, 2004